Submission to APVMA on recombinant canine parvovirus (CPV) strain 630a

Strain 630a is a second-generation recombinant canine parvovirus vaccine strain constructed using recombinant DNA technology. This construction was specifically designed to improve the vaccine strain's ability to overcome maternally derived antibody (MDA) interference while retaining the safety record of the 154 backbone.

Critically, strain 630a is a live, replicating gene-technology organism. Unlike the non-replicative canarypox vectors used in other recombinant veterinary vaccines (e.g., the Recombitek product line), strain 630a is designed to replicate in the vaccinated animal. It infects and replicates in the bloodstream and intestinal mucosa, causes viraemia, and is shed in the faeces of vaccinated dogs. This replication is integral to the vaccine's mechanism of action—it is what produces the strong, rapid immune response that enables MDA breakthrough from 4 weeks of age.

Recommendations for APVMA consideration include:

1. Registration should proceed on the basis of the product's demonstrated safety, efficacy, and critical animal welfare benefit. The MDA breakthrough capability addresses a genuine unmet clinical need.
2. Require mandatory post-market pharmacovigilance with reporting intervals of 6 and 12 months, with specific monitoring for adverse events in target and non-target species and any reports of strain 630a detection in wildlife or non-target domestic animals.
3. Confirm OGTR licensing is in place or will be a condition of registration before marketing.
4. Confirm DAFF Biosecurity have evaluated the biological material component for import.
5. Request, as a post-approval commitment, environmental fate data for strain 630a in representative Australian soil types, including persistence, viability, and any host-range studies relevant to Australian native wildlife. This is justified by the unique combination of properties this product presents: a replicating, shed, environmentally persistent gene-technology organism.
6. Ensure labelling includes: clear identification of the parvovirus component as a gene-technology organism constructed using recombinant DNA technology; a statement that vaccinated animals will shed recombinant vaccine-strain parvovirus in faeces; standard safety warnings; and environmental disposal instructions.
7. Include a labelling advisory that the product contains a live recombinant gene-technology organism that is shed in the faeces of vaccinated animals, and that this may be relevant where animals reside on certified organic, biodiversity, or biosecurity-sensitive properties or areas.

Read the full submission: Submission to APVMA on recombinant canine parvovirus (CPV) strain 630a